Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,294 | 372 | 99.5% |
| Education | $33.57 | 5 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,925 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,322 | 51 | $0 (2024) |
| ABBVIE INC. | $420.47 | 18 | $0 (2024) |
| Amgen Inc. | $401.42 | 19 | $0 (2024) |
| Lilly USA, LLC | $384.53 | 22 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $367.28 | 29 | $0 (2020) |
| PFIZER INC. | $366.11 | 33 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $303.51 | 20 | $0 (2024) |
| GlaxoSmithKline, LLC. | $235.49 | 14 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $219.02 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $629.16 | 28 | AstraZeneca Pharmaceuticals LP ($215.92) |
| 2023 | $738.58 | 28 | Novo Nordisk Inc ($232.65) |
| 2022 | $754.30 | 38 | Novo Nordisk Inc ($301.61) |
| 2021 | $494.99 | 6 | Novo Nordisk Inc ($479.09) |
| 2020 | $512.40 | 24 | AstraZeneca Pharmaceuticals LP ($185.15) |
| 2019 | $1,364 | 77 | AstraZeneca Pharmaceuticals LP ($310.04) |
| 2018 | $1,327 | 60 | Novo Nordisk Inc ($365.99) |
| 2017 | $1,507 | 116 | AstraZeneca Pharmaceuticals LP ($188.53) |
All Payment Transactions
377 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Cardio-renal | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: VACCINE | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: RESPIRATORY | ||||||
| 08/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: DIABETES | ||||||
| 08/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Gastroenterology | ||||||
| 08/13/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $19.48 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Respiratory | ||||||
| 07/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/16/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Diabetes | ||||||
| 07/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Obesity | ||||||
| 05/07/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Diabetes | ||||||
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Respiratory | ||||||
| 04/01/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/19/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Endocrinology | ||||||
| 03/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug), AIRSUPRA | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Obesity | ||||||
| 02/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: NEUROSCIENCE | ||||||
| 02/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Diabetes | ||||||
| 02/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $116.99 | General |
| Category: Respiratory | ||||||
| 02/06/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Inflammation | ||||||
| 01/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: RESPIRATORY | ||||||
| 01/30/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 281 | 752 | $101,392 | $35,802 |
| 2022 | 16 | 1,052 | 1,632 | $231,274 | $84,643 |
| 2021 | 15 | 1,165 | 1,571 | $237,445 | $94,963 |
| 2020 | 17 | 1,194 | 1,587 | $209,805 | $75,740 |
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 74 | 308 | $40,624 | $14,711 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 152 | $27,199 | $8,374 | 30.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 58 | 218 | $25,371 | $7,915 | 31.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 29 | 29 | $2,436 | $2,198 | 90.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 20 | $4,680 | $1,874 | 40.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 25 | $1,082 | $729.25 | 67.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 318 | 519 | $87,918 | $26,044 | 29.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 176 | 497 | $49,700 | $22,739 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 172 | 214 | $47,414 | $13,465 | 28.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 67 | 67 | $14,047 | $8,448 | 60.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 56 | 56 | $4,120 | $3,843 | 93.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 13 | 13 | $4,550 | $3,637 | 79.9% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 14 | 14 | $4,032 | $1,854 | 46.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 61 | 61 | $2,501 | $1,710 | 68.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 34 | 34 | $1,384 | $964.14 | 69.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 17 | 18 | $1,903 | $591.04 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $3,501 | $566.54 | 16.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $3,523 | $276.98 | 7.9% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 52 | 67 | $2,603 | $258.06 | 9.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 20 | 20 | $2,220 | $142.26 | 6.4% |
| 81002 | Urinalysis, manual test | Office | 2022 | 17 | 17 | $636.00 | $58.66 | 9.2% |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | Office | 2022 | 11 | 11 | $1,222 | $43.84 | 3.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 331 | 618 | $100,108 | $34,764 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 222 | 314 | $66,568 | $23,738 | 35.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 112 | 112 | $22,512 | $14,573 | 64.7% |
About Dr. Thomas Darrell, M.D
Dr. Thomas Darrell, M.D is a Family Medicine healthcare provider based in Fuquay Varina, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1023003134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Darrell, M.D has received a total of $7,327 in payments from pharmaceutical and medical device companies, with $629.16 received in 2024. These payments were reported across 377 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($7,294).
As a Medicare-enrolled provider, Darrell has provided services to 3,692 Medicare beneficiaries, totaling 5,542 services with total Medicare billing of $291,149. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Fuquay Varina, NC
- Active Since 09/14/2005
- Last Updated 07/09/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1023003134
Products in Payments
- FARXIGA (Drug) $860.38
- RYBELSUS (Drug) $464.17
- Ozempic (Drug) $451.12
- Victoza (Drug) $289.19
- XARELTO (Drug) $270.17
- Aimovig (Biological) $220.95
- MOUNJARO (Drug) $208.01
- Rybelsus (Drug) $200.51
- Wegovy (Drug) $179.70
- Synthroid (Drug) $172.51
- AIRSUPRA (Drug) $163.93
- Androgel (Drug) $156.91
- Saxenda (Drug) $152.63
- Xultophy 100/3.6 (Drug) $144.45
- JARDIANCE (Drug) $141.72
- TRADJENTA (Drug) $140.50
- TOUJEO (Drug) $134.08
- BREZTRI (Drug) $128.13
- MYDAYIS (Drug) $127.73
- TRELEGY ELLIPTA (Drug) $120.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Fuquay Varina
Tiffany Lowe Clayton, Do, DO
Family Medicine — Payments: $294,724
Dr. Jason Devente, M.d, M.D
Family Medicine — Payments: $5,045
Mary Jones, Md, MD
Family Medicine — Payments: $1,152
Dr. Sharon Speed, M.d, M.D
Family Medicine — Payments: $617.56
Latoya Woods, D.o, D.O
Family Medicine — Payments: $602.36
David Keith, M.d, M.D
Family Medicine — Payments: $564.27